Evgen Pharma (GB:TCF) has released an update.
TheraCryf plc has announced that research on their drug SFX-01 as a radiosensitiser in Rhabdomyosarcoma, a common childhood soft tissue sarcoma, has been published in BMC Cancer. The studies conducted by the Sapienza University of Rome indicate that when used with radiotherapy, SFX-01 could potentially enhance treatment efficacy. This breakthrough offers hope for improved therapeutic options for patients who have limited alternatives.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
